Covid-19: International Response

Gagan Mohindra Excerpts

Wednesday 6th May 2020 Commons Chamber

[Anne-Marie Trevelyan]

I thank the hon. Lady for her questions. I will do my best to answer them all in turn.

On funding allocation, we have so far committed £276 million for resilience, with multinational organisations and UN appeals alongside the International Red Cross and the Unilever project. Some £380 million is focused on the vaccine, drugs and therapeutics space through CEPI, FIND—the Foundation for Innovative New Diagnostics—Wellcome and so on, alongside the economic response with the IMF commitment of £150 million and the Gavi investment, which will all be part of the delivery of the vaccine.

I was not aware of the UNICEF statistics on vaccine treatment numbers that the hon. Lady raised, so I will ask my officials to get in touch with her and look closely at that. I thank her for raising that issue with me today.

The event on Monday was co-ordinated by the EU and co-hosted by a number of leaders, including our own Prime Minister. It was a coalition of the willing: a gathering together of those, mostly European, nations who wanted to show their support and solidarity on the international front. We are working closely with the USA on vaccines and more widely on delivery. That continues separately. The USA’s commitment is enormous, and not just internally. I was talking with the new United States Agency for International Development chief, John Barsa earlier in the week about how they are going to focus in the medium term on the substantial commitment the US always makes to supporting vulnerable countries. That will be an ongoing conversation and I think the commitment from USAID is unstinting in that space.

The hon. Lady raised the very important issue of how the conditions go with the funding we put in. That is why we have invested our funds through CEPI and FIND. Both organisations put their money into appropriate projects with an understanding and a contractual relationship that ensures that those scientific programmes will then be accessible to all. It is a really important and secure way—if that is the right way to describe it—of ensuring that UK taxpayers’ money really does reach vulnerable countries when the technologies are discovered.

I completely agree with the hon. Lady on food insecurity. This is absolutely a critical question that we must not lose sight of as we are fighting this disease in the short term. The impact on the most vulnerable countries of food insecurity has not gone away. The threat of locust plagues in just one part of the globe is one critical function we need to get on top of. We are starting to see, as everyone looks up from their own domestic challenges, the great challenge that we have. If we do not support tackling all the other critical preventable death areas, we will find that we cannot tackle this disease. As I said earlier, no one is safe until we are all safe.

[Mr Gagan Mohindra (South West Hertfordshire) (Con)]

I thank my right hon. Friend for her statement. She will be aware of the World Health Organisation, and there have been some criticisms of it. Do we agree with those criticisms, and are we reviewing the funding of the WHO?

[Anne-Marie Trevelyan]

I thank my hon. Friend for that really important question. I do not think anyone would suggest that the WHO is a perfect organisation, but it is an extraordinary organisation, because it has the legitimacy of pretty much every country on the planet. It is a profoundly experienced and wise organisation in all matters health, and it has the ability to reach and to support every country around the globe. We are one of its largest core funders, we have been for many years and we will continue that. There are always lessons to be learned, and in something like a global pandemic, we will no doubt be in a whole new territory of lessons to be learned and of understanding where countries and multilateral organisations were able to do well, but the reality is that the WHO is the central point—the central hub—and we will continue to support it absolutely throughout the crisis and to work, as we have in the past, to find ways to help it become a slicker, more effective organisation in the future.